Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $289.03 (market cap $39.89B), while Rex Fang & Innovation Equity Premium Income ETF trades at $42.24. The key difference: Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FEPI | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $49.54 |
52-Week Low | $278.09 | $38.13 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $42.68, up 0.19% on the day, with a bearish technical signal from moving averages. The ETF generates high income through weekly dividends, recently transitioning to weekly distributions to enhance cash flow. Its covered call strategy on concentrated tech and AI stocks provides a high yield but limits upside potential and exposes investors to net asset value erosion during market downturns.
The outlook for FEPI hinges on its ability to sustain high dividend yields amid volatile tech markets. Investment opportunities include consistent weekly income, but risks involve capped gains from call writing and sensitivity to tech sector swings. Analyst sentiment is mixed, balancing yield appeal with structural limitations that may hinder long-term growth compared to broad market ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
